$HALB Chairman, President & CEO, William A. Hartman, added, "We have examined a number of extracorporeal treatment variations, and this one seems to have the most universal application. This process only requires that we create an antibody which has an affinity to the target antigen and can bind with the designed metallic moiety. Once fully developed, this methodology could theoretically end the possibility of any and all future infectious pandemics. This revolutionary technology is designed to preclude the possibility of any potential resistance by any infectious pathogen - tuberculosis, malaria, sepsis, etc."